background
oral
lichen
planu
olp
seen
frequent
patient
hepat
c
viru
hcv
infect
aim
studi
evalu
occurr
oral
candidiasi
mucos
lesion
xerostomia
interferon
ifn
therapi
hcv
infect
method
patient
hcvinfect
liver
diseas
treat
ifn
therapi
hospit
mean
age
year
attend
receiv
administr
ifn
week
identifi
examin
candida
infect
oral
lesion
measur
salivari
flow
serolog
assay
also
carri
result
cultur
candida
tongu
surfac
posit
patient
hcv
infect
least
ifn
therapi
c
albican
common
speci
isol
incid
candida
treatment
ifn
increas
treatment
addit
oral
mucos
lesion
observ
patient
olp
three
angular
cheiliti
three
recurr
aphthou
stomat
one
olp
occur
one
patient
treatment
ifn
one
treatment
one
end
treatment
oral
lesion
treat
topic
steroid
compar
characterist
patient
candida
detect
least
ifn
therapi
group
patient
candida
detect
ifn
therapi
group
preval
oral
mucos
lesion
incid
extern
use
steroid
group
significantli
higher
group
averag
bodi
weight
group
decreas
significantli
compar
group
salivari
flow
decreas
subject
throughout
cours
ifn
treatment
return
th
month
end
treatment
group
level
albumin
begin
th
month
ifn
administr
lower
group
accord
multivari
analysi
one
factor
presenc
oral
mucos
lesion
associ
detect
candida
adjust
odd
ratio
factor
confid
interv
pay
attent
oral
candidiasi
well
oral
mucos
lesion
patient
weight
loss
ifn
treatment
hepat
c
major
global
public
health
problem
hepat
c
viru
hcv
infect
one
main
caus
cirrhosi
hepatocellular
carcinoma
hcc
interferon
ifn
therapi
reduc
incid
hepatocarcinogenesi
patient
hepat
c
improv
longterm
prognosi
standard
therapi
combin
pegyl
interferon
pegifn
ribavirin
rbv
addit
pegifn
rbv
telaprevir
tripl
therapi
new
strategi
expect
erad
hcv
even
patient
infect
difficulttotreat
genotyp
strain
although
advers
effect
anemia
rash
frequent
extrahepat
manifest
hcv
infect
numer
common
diseas
associ
hcv
hematolog
dermatolog
renal
rheumatolog
diseas
lichen
planu
lp
chronic
mucocutan
diseas
affect
oral
mucosa
skin
genit
mucosa
scalp
nail
signific
associ
lp
chronic
hcv
infect
report
japan
itali
spain
previous
report
hcv
associ
close
extrahepat
manifest
oral
lp
olp
report
examin
hepat
c
patient
oral
lesion
ifn
treatment
olp
seen
olp
occur
becom
exacerb
persist
ifn
treatment
hepat
c
even
serum
hcv
rna
becom
neg
studi
suggest
olp
pathogenesi
hepat
c
may
attribut
host
factor
induc
hcv
infect
rather
direct
patholog
effect
viru
candida
gener
caus
problem
healthi
peopl
candida
commonli
cultur
oral
mucos
lesion
overgrowth
candida
howev
lead
local
discomfort
alter
tast
sensat
dysphagia
esophag
overgrowth
result
poor
nutrit
slow
recoveri
prolong
hospit
stay
risk
factor
associ
symptomat
candidiasi
includ
local
system
immunosuppress
haematolog
disord
broadspectrum
antibiot
use
inhal
system
steroid
xerostomia
diabet
wear
dentur
obtur
orthodont
applianc
smoke
candida
report
found
olp
case
treatment
olp
steroid
known
lead
secondari
yeast
infect
may
complic
treatment
olp
c
albican
c
glabrata
c
tropicali
isol
olp
lesion
treat
topic
steroid
xerostomia
known
one
advers
event
observ
ifn
therapi
aghemo
et
al
report
dri
mouth
occur
ifn
therapi
result
revers
inhibit
salivari
gland
function
rbv
caus
salivari
gland
hypofunct
also
report
salivari
flow
rate
ifn
therapi
japanes
phase
iii
trial
pegifn
rbv
involv
patient
chronic
hepat
c
includ
patient
ifn
treatmentna
genotyp
patient
patient
svr
ifn
therapi
patient
develop
dri
mouth
hand
japanes
phase
iii
trial
pegifn
rbv
involv
chronic
hepat
c
patient
includ
patient
week
treatment
durat
genotyp
high
viru
load
patient
week
treatment
durat
other
patient
develop
dri
mouth
report
oral
candida
ifn
treatment
chronic
hepat
c
patient
aim
studi
determin
incid
candida
well
develop
olp
angular
cheiliti
recurr
aphthou
stomat
xerostomia
cours
ifn
treatment
patient
chronic
hepat
c
patient
total
consecut
hcvinfect
patient
ifn
therapi
plan
checkup
oral
mucos
diseas
base
hospit
clinic
pathway
digest
diseas
center
kurum
univers
hospit
japan
juli
octob
digest
diseas
center
physician
surgeon
radiologist
oral
surgeon
examin
patient
special
area
seventeen
patient
agre
simultan
consult
hepatologist
oral
surgeon
digest
diseas
center
order
receiv
administr
pegifn
oral
examin
per
week
patient
consult
doctor
everi
week
fourteen
patient
complet
therapi
three
patient
discontinu
ifn
treatment
nullrespons
system
autoimmun
disord
autoimmun
hepat
syndrom
consid
exclus
criteria
ifn
therapi
patient
men
women
complet
ifn
therapi
examin
rang
age
year
averag
age
year
eleven
patient
hcv
genotyp
receiv
administr
pegifnrbv
week
two
patient
hcv
genotyp
receiv
administr
pegifnrbv
week
one
patient
liver
cirrhosi
hcv
genotyp
receiv
administr
ifn
beta
week
question
subject
frequenc
toothbrush
use
headband
fiber
daiichi
medic
co
ltd
bright
luce
mucos
examin
oral
biopsi
perform
patient
diagnosi
olp
made
basi
clinic
andor
histopatholog
featur
patient
examin
ifn
therapi
begin
nd
week
ifn
administr
begin
rd
month
ifn
administr
begin
th
month
ifn
administr
end
ifn
therapi
th
month
end
treatment
patient
weigh
hospit
visit
patient
complain
haphalgesia
burn
sensat
oral
musoc
lesion
prescrib
extern
steroid
dexamethason
dexaltin
w
nippon
kayaku
co
ltd
tokyo
japan
triamcinolon
acetonid
aphthas
w
taisho
toyama
pharmaceut
co
ltd
tokyo
japan
beclometason
dipropion
salcoat
w
teijin
pharma
co
ltd
tokyo
japan
salivari
flow
measur
patient
use
simpl
lowcost
test
detect
xerostomia
requir
chew
piec
gauz
min
salivari
flow
rate
min
judg
decreas
salivari
secret
patient
examin
ifn
therapi
begin
nd
week
ifn
administr
begin
rd
month
ifn
administr
begin
th
month
ifn
administr
end
ifn
therapi
th
month
end
treatment
examin
candida
speci
surfac
tongu
patient
chronic
liver
diseas
ifn
therapi
surfac
tongu
rub
ten
time
cotton
swab
place
chromagar
candida
slant
chromagar
candida
medium
chromagar
pari
franc
prepar
accord
manufactur
instruct
swab
inocul
chromagar
candida
medium
rotat
swab
head
surfac
medium
plate
incub
c
h
coloni
morpholog
colour
descript
assign
standard
manner
singl
investig
patient
diagnos
candidiasi
complain
burn
sensat
oral
caviti
administ
antifung
agent
miconazol
florid
w
mochida
pharmaceut
co
ltd
tokyo
japan
itraconazol
itrizol
w
janssen
pharmaceut
kk
tokyo
japan
visit
hospit
administr
ifn
patient
test
platelet
plt
white
blood
cell
wbc
hemoglobin
hb
follow
liver
function
test
serum
alanin
aminotransferas
alt
aspart
aminotransferas
ast
lactat
dehydrogenas
ldh
total
bilirubin
tbil
albumin
alb
presenc
antissa
antissb
antibodi
patient
test
use
enzymelink
immunosorb
assay
elisa
normal
level
antissa
ssaro
e
tfb
ink
japan
antissb
ssbla
e
tfb
ink
japan
less
uml
respect
hcv
rna
analyz
serum
quantit
pcr
assay
coba
amplicor
hcv
monitor
v
test
coba
ampliprepcoba
taqman
hcv
test
roch
molecular
system
new
jersey
us
hcv
genotyp
determin
polymeras
chain
reaction
assay
use
mixtur
primer
subtyp
report
previous
ultrasonograph
examin
perform
patient
order
investig
shape
liver
lesion
occupi
liver
comput
tomographi
liver
biopsi
perform
patient
use
possibl
predictor
progress
liver
cirrhosi
includ
serum
alb
tbil
prothrombin
time
plt
investig
undertaken
understand
consent
particip
subject
conduct
full
accord
ethic
principl
world
medic
associ
declar
helsinki
ethic
committe
kurum
univers
conclud
studi
includ
ethic
guidelin
studi
medic
practic
aim
diagnosi
treatment
data
express
mean
standard
error
differ
two
group
analyz
use
mannwhitney
u
test
wilcoxon
test
fisher
exact
test
differ
judg
signific
p
twotail
adjust
odd
ratio
calcul
use
logist
regress
analysi
statist
analys
conduct
use
jmp
version
sa
institut
cari
nc
usa
level
statist
signific
defin
cultur
candida
tongu
surfac
posit
seven
patient
hcv
infect
least
ifn
therapi
tabl
show
associ
incid
posit
candida
cultur
ifn
therapi
incid
posit
candida
cultur
case
c
albican
ifn
therapi
case
c
albican
begin
nd
week
ifn
administr
case
c
albican
case
c
albican
c
parapsilosi
begin
rd
month
ifn
administr
case
c
albican
begin
th
month
ifn
administr
case
c
albican
case
c
lusitania
end
ifn
therapi
case
c
albican
case
c
albican
c
tropicali
th
month
end
treatment
c
albican
common
speci
isol
tongu
surfac
incid
candida
treatment
ifn
increas
treatment
oral
mucos
lesion
observ
patient
three
olp
men
woman
three
angular
cheiliti
women
one
recurr
aphthou
stomat
woman
olp
occur
one
patient
treatment
ifn
one
treatment
one
end
treatment
tabl
patient
year
old
male
eros
olp
ifn
therapi
lesion
becam
exacerb
ifn
therapi
abl
complet
therapi
improv
steroid
applic
administ
antifung
agent
two
patient
no
tabl
candidiasi
complain
burn
pain
prescrib
extern
steroid
six
patient
no
tabl
oral
mucos
lesion
compar
characterist
patient
group
candida
detect
least
ifn
therapi
patient
group
candida
detect
treatment
tabl
preval
oral
mucos
lesion
incid
extern
use
steroid
respect
group
respect
group
preval
oral
mucos
lesion
incid
extern
use
steroid
significantli
higher
group
group
diagnosi
oral
mucos
diseas
group
includ
olp
angular
cheiliti
recurr
aphthou
stomat
group
olp
bodi
weight
decreas
significantli
group
ifn
therapi
compar
group
number
neutrophil
plt
alb
hb
decreas
subject
throughout
cours
ifn
treatment
group
level
alb
begin
th
month
ifn
administr
lower
group
tabl
number
time
teeth
brush
everi
meal
lower
group
group
salivari
flow
decreas
subject
throughout
cours
ifn
treatment
return
th
month
end
treatment
tabl
salivari
flow
min
ifn
therapi
min
begin
nd
week
ifn
administr
min
begin
rd
month
ifn
administr
min
begin
th
month
ifn
administr
g
min
end
ifn
therapi
min
th
month
end
treatment
signific
differ
salivari
flow
group
group
accord
multivari
analysi
one
factor
presenc
oral
mucos
lesion
associ
detect
candida
adjust
odd
ratio
factor
confid
interv
oral
candida
albican
known
isol
patient
olp
candida
albican
isol
special
virul
attribut
might
cofactor
contribut
develop
olp
especi
eros
olp
eros
olp
caus
spontan
pain
eat
toothbrush
report
detect
oral
candida
ifn
treatment
chronic
hepat
c
studi
candida
detect
patient
hcvrelat
chronic
liver
diseas
receiv
ifn
treatment
signific
factor
associ
candida
presenc
oral
mucos
lesion
associ
ifn
therapi
oral
lesion
treat
topic
steroid
found
correl
hcv
genotyp
level
hcv
rna
ifn
type
dose
administr
schedul
effect
ifn
therapi
candida
detect
poor
oral
health
report
hcvinfect
patient
coat
et
al
report
experi
dental
cari
significantli
wors
hcvinfect
subject
patient
gener
griffin
et
al
found
patient
rheumatoid
arthriti
diabet
liver
condit
twice
like
urgent
need
dental
treatment
patient
diseas
document
high
burden
unmet
dental
care
need
among
patient
chronic
diseas
author
show
hcv
strongest
predictor
patient
report
poor
oral
health
studi
high
rate
detect
candida
speci
patient
brush
teeth
everi
meal
compar
oral
hygien
encourag
patient
ifn
treatment
previou
studi
dental
problem
delay
initi
ifn
therapi
day
hcvinfect
patient
treat
ifn
manag
intens
oral
care
lower
resist
infect
therapi
regard
pain
olp
conceiv
oral
caviti
hcv
infect
like
becom
less
healthi
one
without
hcv
infect
refrecareh
w
en
otsuka
pharmaceut
co
ltd
iwat
japan
oral
care
gel
contain
hinokitiol
remov
stain
teeth
gener
oral
debri
effect
prevent
breath
odor
gum
diseas
hinokitiol
signific
antimicrobi
efficaci
staphylococcu
aureu
propionibacterium
acn
coronaviru
trichophyton
candida
albican
report
oral
care
gel
improv
subject
symptom
patient
olp
ifn
therapi
hcv
infect
associ
variou
side
effect
includ
greater
level
fatigu
loss
appetit
weight
loss
sleep
problem
depress
present
studi
weight
loss
ifn
therapi
lead
oral
candidiasi
weight
loss
consid
import
risk
factor
oral
candidiasi
backbrito
gn
et
al
demonstr
eat
disord
lead
increas
oral
candida
carriag
studi
show
hypoalbuminemia
ifn
therapi
might
lead
oral
candidiasi
report
previous
strong
associ
hypoalbuminemia
mortal
hyperendem
area
x
town
hcv
infect
japan
hypoalbuminemia
independ
risk
factor
develop
olp
sever
studi
shown
associ
hcv
symdrom
ss
studi
demonstr
salivari
flow
patient
hcv
infect
decreas
ifn
treatment
increas
treatment
variou
investig
report
high
preval
oral
candida
speci
patient
ss
compar
healthi
control
japanes
hcvinfect
patient
tend
older
countri
older
age
favor
onset
hcc
addit
oral
candidiasi
underdiagnos
among
elderli
therefor
requir
care
attent
oral
caviti
patient
receiv
ifn
therapi
conclus
data
show
ifn
therapi
led
develop
oral
mucos
lesion
lead
oral
candidiasi
inhibit
salivari
secret
pay
attent
oral
candidiasi
well
addit
oral
mucos
lesion
patient
weight
loss
ifn
treatment
patient
hcv
infect
emphas
paramount
import
oral
manag
